Skip to search formSkip to main contentSkip to account menu

dasatinib 70 MG Oral Tablet [Sprycel]

Known as: Sprycel 70 MG Oral Tablet 
National Institutes of Health

Related topics

Related topics

13 relations
Croscarmellose SodiumLactose MonohydrateMagnesium stearateOral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic…
Abstract 172 Background. Dasatinib (Sprycel®) is a potent inhibitor of BCR-ABL and SRC family kinases. Based on the rapid and… 
2010
2010
Depigmentazione cutanea ed incanutimento in paziente pediatrico affetto da LLA e in terapia con Dasatinib
This article reports the case of a paediatric patient who experienced depigmentation of his hair, eyelashes and eyebrows, four-to… 
2008
2008
Recommandations pour la gestion des effets indésirables du traitement par dasatinib (Sprycel ® ) au cours de la leucémie myéloïde chronique et des leucémies aiguës lymphoblastiques à chromosome…
Le dasatinib (Sprycel ®) est une nouvelle therapeutique ciblee, utilisee depuis 2005 dans le traitement des patients atteints de… 
2007
2007
A phase I study (CA180021-Segment 2) of dasatinib in patients (pts) with advanced solid tumors
14042 Background: SPRYCEL™ is a potent, orally active, multi-targeted kinase inhibitor, active against BCR-ABL and SRC family… 
2006
2006
Efficacy of Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Resistant to or Intolerant of Imatinib: Updated Results of the CA180013 ‘START-C’ Phase II…
Dasatinib (SPRYCEL ® , formerly BMS-354825) is an oral, multi-targeted, kinase inhibitor of BCR-ABL and SRC kinases, approved by… 
2006
2006
Dasatinib (SPRYCEL®) in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Who Are Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results from the CA180-015…
Dasatinib (SPRYCEL®, formerly BMS-354825) is a novel, oral, multi-targeted kinase inhibitor of BCR-ABL and SRC. Relapsing pts… 
2006
2006
Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study…
Pts with CML resistant to im have few therapeutic options. A growing body of evidence suggests that treatment outcomes can be… 
2006
2006
Dasatinib (SPRYCEL®) 140 mg Once Daily (QD) vs 70 mg Twice Daily (BID) in Patients (pts) with Advanced Phase Chonic Myeloid Leukemia (ABP-CML) or Ph(+) ALL Who Are Resistant or Intolerant to Imatinib…
Dasatinib (SPRYCEL®, formerly BMS-354825), an oral multi-targeted kinase inhibitor of BCR-ABL and SRC kinases, has been shown to… 
2006
2006
Dasatinib (Sprycel™) Therapy for Patients with Systemic Mastocytosis.
Background Systemic mastocytosis (SM) is characterized by abnormal proliferation and accumulation of neoplastic mast cells… 
2006
2006
Dasatinib (SPRYCEL®) in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase (CML-CP).
Dasatinib (SPRYCEL ® , formerly BMS-354825) is a multi-targeted kinase inhibitor of BCR-ABL and SRC. Based on its high level of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)